×

Biotech and Pharmaceuticals Life Sciences

  • *Sees deal adding 30 cents to adjusted EPS in first year. May 15- Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in production and services for the biopharma industry. Thermo will also assume $2 billion in net debt, putting the cost of the...

  • LONDON, May 12- A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business. Shares in AstraZeneca extended gains to be up by 9.1 percent by mid-afternoon, the top FTSE 100 riser,...

  • LONDON, May 12- A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced the risk of death from advanced lung cancer, giving it a lead over rivals as it seeks to transform its oncology business. Shares in AstraZeneca were up 4.7 percent by 1000 GMT, the top FTSE 100 riser, and the company said it was in talks with the authorities over plans for...

  • LONDON, May 12- AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday. The trial results are a boost for a product the company hopes will become a blockbuster drug with sales in the billions of dollars. "These are highly encouraging...

  • *Danish group looking for new drugs "adjacent" to diabetes. LONDON, May 11- Hit by pricing pressure in its core insulin business, Danish drugmaker Novo Nordisk is looking at new treatments for obesity- a major cause of diabetes- to help revive its growth. By contrast, Novo's newly approved anti-obesity injection Saxenda, launched in 2015 and containing the same GLP-1...

  • NEW YORK, May 10- U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront. Shares of Sangamo jumped 41 percent to $6.15 in after-the-bell trading. Michael Goettler, global...

  • *Analysts say failure puts approval at risk. ZURICH, May 10- Roche's Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine. Roche, the world's biggest maker of cancer drugs, had won...

  • *AstraZeneca sets durvalumab price at $15,000/ month. Leerink analyst Seamus Fernandez sees durvalumab capturing a modest 10 percent of the estimated $2.3 billion global bladder cancer market, while AstraZeneca in 2014 put the drug's peak sales in all cancers at $6.5 billion, including combination use. The U.S. Food and Drug Administration said late on Monday...

  • *AstraZeneca sets durvalumab price at $15,000/ month. May 1- U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars. The U.S. Food and Drug Administration said on Monday it granted accelerated...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • LONDON, April 27- AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Despite income from disposals and external deals, first-quarter revenue fell 12 percent to $5.4 billion, although core...

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 25- German healthcare group Fresenius SE& Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars arm of Germany's Merck KGaA. But his successor, former finance chief Stephan Sturm, is lifting the pace, having already bought a Spanish hospital...

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 24- German healthcare conglomerate Fresenius SE& Co KGaA revved up the pace of its deals by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion, and in a separate agreement, the biosimilars unit of German peer Merck KGaA. A lot has been done in that area in the recent past, "Fresenius Chief Executive Stephan...

  • LONDON, April 20- The biotech company behind the Western world's first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially since the drug was first approved in Europe nearly five years ago, a spokeswoman for Dutch-based UniQure said on...

  • LONDON, April 18- Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business. The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are...

  • WASHINGTON, April 14- The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday. FDA indicated that additional clinical data was needed to determine the most appropriate doses of the drug, Olumiant, known also as baricitinib, and to further...

  • CNBC reporter Christina Farr discusses her exclusive scoop that Apple is moving into life science with a team working on glucose-sensing technology.

  • April 3- Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The industry's pipeline of cancer drugs expanded by 63 percent between 2005 and 2015, according to the QuintilesIMS Institute, and a good number are reaching the market.

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known...